News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TiGenix : Licenses Exclusive Marketing And Distribution Rights For Chondrocelect To Swedish Orphan Biovitrum


4/3/2014 8:13:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEUVEN, Belgium, April 3, 2014 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has licensed the marketing and distribution of ChondroCelect, the cell-based medicinal product for the repair of cartilage defects of the knee, to the international specialty healthcare company dedicated to rare diseases, Swedish Orphan Biovitrum AB ('Sobi', NASDAQ OMX Stockholm: SOBI).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES